[Chemotherapeutic effects in hypoplastic leukemia].
Clinical effects of a low dose of behenoyl ara-C (LD-BHAC) and K-18, an IgG-melphalan conjugate, were studied in hypoplastic leukemia (HL). Among 8 cases of HL treated with LD-BHAC regimen, in which 50 mg BHAC was administered daily by one-hour drip infusion for 14 days, 4 achieved complete remission (CR) and 2, partial remission (PR). The response rate (CR + PR) was 75%. Hematological toxicities were observed in most of the cases. The peak level of serum ara-C concentration, 3.62-18.9 ng/ml (mean: 11.74 ng/ml), was observed at cessation of infusion, and an ara-C level of 2.75-48.9 ng/ml (mean: 3.45 ng/ml) was still present in the blood 6 hours after cessation of infusion. Six cases of HL were treated with K-18. Eight tablets of K-18, containing 30 mg per tablet, were given daily. Two of 6 cases achieved CR with little hematological toxicities. LD-BHAC and K-18 can be expected in the treatment of hypoplastic leukemia and its related diseases such as hypoplastic preleukemia in the aged.
Takahashi
I
I
Second Dept. of Medicine, Okayama University Medical School.
Nakada
H
H
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000922:Immunotoxins / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008558:Melphalan / Q000627:therapeutic use*; D008875:Middle Aged; D011289:Preleukemia / Q000628:therapy*
D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D000922:Immunotoxins; D003561:Cytarabine; C015019:enocitabine; D008558:Melphalan